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Abstract
Background: Streptokinase (SK) is an effective fibrinolytic agent for the treatment of acute myocardial
infarction (AMI). The objective of the present study was to assess the adverse drug reactions (ADRs)
associated with intravenous recombinant SK in patients with AMI in routine clinical practice.
Methods: A national, prospective and spontaneous reporting-based pharmacovigilance program was
conducted in Cuba. Patient demographics, suspected ADR description, elements to define causality, and
outcomes were documented and analyzed.
Results: A total of 1496 suspected ADRs identified in 792 patients out of the 1660 (47.7 %) prescriptions
reported in the program, were received from July 1995 to July 2002. Most of the patients (71.3%) were
male, 67.2% were white and mean age was 61.6 ± 13.0 years. The mean time interval between the onset
of symptoms and the start of the SK infusion was 4.9 ± 3.7 h. The most frequently reported ADRs were
hypotension, arrhythmias, chills, tremors, vomiting, nauseas, allergy, bleeding and fever. ADR severity was
38% mild, 38% moderate, 10% severe, and 4% very severe. Only 3 patients with hemorrhagic stroke were
reported. Seventy-two patients died in-hospital mainly because of cardiac causes associated with the
patient's underlying clinical condition. Mortality was 3 times more likely in patients suffering arrhythmias
than in those without this event (odds ratio 3.1, 95% CI: 1.8 to 5.1). Most of the reported ADRs were
classified as possibly or probably associated with the study medication.
Conclusion:  Recombinant SK was associated with a similar post-marketing safety profile to those
suggested in previous clinical trials.
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Background
Streptokinase (SK) is an indirect fibrinolytic agent that
interacts with plasminogen, forming an active complex
with protease activity that converts plasminogen to plas-
min [1]. SK efficacy with regard to mortality reduction in
patients with acute myocardial infarction (AMI) has been
demonstrated in large, placebo-controlled trials [2,3].
A SK produced by recombinant DNA techniques (rSK) has
been evaluated previously in clinical trials in AMI
patients. The first studies suggested that rSK produced the
same benefits that were described for natural SK [4,5].
These results were further supported by the Thrombolysis
with Recombinant Streptokinase in Acute Myocardial Inf-
arct (TERIMA)-1 trial, a multicenter, randomized, com-
parative study of rSK vs. natural SK in 224 patients [6].
Both SKs behaved similarly regarding coronary patency at
8 days after thrombolysis and the changes induced on
fibrinogen, fibrinogen-degradation-products, and
thrombin time. They were also similar with respect to
anti-SK antibodies titers and their anti-SK neutralizing
activities [7]. The effect on AMI patients' in-hospital mor-
tality was evaluated in a 2923-patients, multicenter, open,
phase IV, clinical study (TERIMA-2) [8]. In-hospital
10.4% mortality was found which represented a 4% abso-
lute and a 28.3% relative lethality reduction as compared
to a survey made before rSK treatment was introduced.
Clinical trials are usually conducted on a limited number
of patients with restrict selection and handling criteria and
thus only the most frequent reactions are identified. Post-
marketing monitoring is an important procedure to detect
some reactions that can become apparent only when the
drug is used in a large and varied population. Therefore,
an active surveillance program provides a vital service to
the heath care system to identify and assess early warning
signals, and when appropriate, to take preventive actions
to minimize the deleterious effects of drugs.
An adequate safety profile for rSK was observed in clinical
trials but it was unknown whether similar results would
be found in routine clinical practice. This concern was par-
ticularly important for rSK given its nature as a fibrinolytic
drug, the potential antigenic capacity due to its bacterial
origin, the novelty of the product production process, and
its use in emergency situations. Therefore, the further
extension of this treatment in Cuba was monitored
through an appropriate pharmacovigilance program with
the aim to assess rSK safety in AMI patients in routine
practice. This paper reports the analysis of data collected
after 7 years of such surveillance system implementation.
Methods
A national, prospective and spontaneous reporting-based
pharmacovigilance study was conducted in Cuba. This
study was extended to the 14 provinces throughout the
different levels of the healthcare system, including munic-
ipal, provincial, and clinical-surgical hospitals as well as
third-level specialized cardiology units. An adverse drug
reaction (ADR) report form was designed. It explicitly
asked for the most commonly rSK-associated ADRs and
also requested for other reactions. The Clinical Trials Divi-
sion of the Center for Biological Research and the
National Network of Pharmacoepidemiology (NNP) were
responsible for the distribution to the hospital services,
gathering and quality assessment of ADR report forms.
This network is coordinated by the Centre for the Devel-
opment of Pharmacoepidemiology and its National
Coordinating Unit of Pharmacovigilance, as previously
described [9]. Since 1994 Cuba is member of the WHO
International Drug Monitoring Program.
The rSK (Heberkinasa, Heber Biotec, Havana) studied in
this pharmacovigilance system is indicated in AMI as soon
as possible, before 12 hours of symptoms onset, in
patients without contraindications for thrombolysis. The
recommended dose is 1 500 000 IU during 1 hour,
through a peripheral vein infusion. Suspected ADRs were
identified by physicians through a direct patient evalua-
tion during and after SK administration, as part of the AMI
patient assessment. Patient demographics, time between
symptom onset and SK infusion, concomitant therapy,
outcome (if death and cause of death) and ADR descrip-
tion, including duration, severity, treatment and need for
discontinuation, were documented.
An ADR was defined as any noxious, unintended, and
undesired effect of a drug that was observed at doses usu-
ally administered therapeutically in humans. The medical
terminology such as signs and symptoms definition as
well as disease or syndrome diagnostic criteria was left to
the attending physicians' judgment so that it could reflect
routine clinical practice. A temporal or possible associa-
tion was sufficient for a report to be made.
A qualitative assessment was used to classify the causal
relationship as definite, probable, possible or doubtful
[10]. According to this method, a reaction was classified as
definite if (1) followed a reasonable temporal sequence
after drug administration; (2) followed a known pattern
of response to the suspected drug; (3) could not be
explained by concurrent disease or other drugs; and (4)
was confirmed by improvement upon removal of the drug
and by reappearance on rechallenge. It was considered as
probable if it had the criteria (1), (2), (3) and was con-
firmed on suspension of the drug but not on rechallenge.
A reaction was defined as possible if followed a reasona-
ble time sequence to administration of the drug, but could
also be explained by concurrent disease or other drugs.BMC Clinical Pharmacology 2005, 5:5 http://www.biomedcentral.com/1472-6904/5/5
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Finally, a reaction that was more likely related to factors
other than the suspected drug was classified as doubtful.
The severity of ADRs was classified in four levels: (1) mild
if no therapy was necessary, (2) moderate if needed spe-
cific treatment, (3) severe when hospitalization or its pro-
longation was required, and (4) very severe if a reaction
was potentially life-threatening or contributed to patient's
death.
The causality assessment, as well as the severity analysis,
were undertaken by members of the NNP taking into
account the reporting physician's criteria, and were further
reviewed by the responsible investigators.
The study was sanctioned by the Scientific Committee of
the Center for Biological Research. As the study did not
involve any intervention apart from the usual medical
procedures, and confidentiality of the subjects was main-
tained, ethics approval and patients' informed consent
were not required. The analysis of all ADRs was reported
to the National Regulatory Authority.
Data management and statistical analyses
Databases were double-entered and validated on Micro-
soft Visual FoxPro version 5.0 and then imported into
SPSS version 11.5 for further analysis. Continuous varia-
bles are given as means ± standard deviations (SD),
whereas discrete variables are given as frequency distribu-
tions. Univariate analyses were performed to identify the
variables that could influence on adverse reactions and
mortality. The analyses were assessed by the χ2 or Fisher's
exact tests, depending on the minimum expected values of
the tables. A logistic regression analysis was done with var-
iables that resulted statistically significant. The level of sig-
nificance chosen was p = 0.05.
Results
A total of 1660 notifications of SK prescriptions was
received from July 1995 to July 2002 from 50 hospitals.
Of them, 792 (47.7%) reported suspected ADRs. The
baseline characteristics of the patients are shown in Table
1. Most of the subjects (71.3%) were male, 67.2% were
white and the mean age was approximately 62 years. Age
was gender-related: women were 4.4 (95% confidence
interval [CI]: 2.9 to 5.9) years older. The mean time inter-
val between the onset of symptoms and the start of the SK
infusion was 4.9 ± 3.7 hours. Concomitant acetylsalicylic
acid was administered in 81% of the patients.
We found 1496 suspected ADRs identified in 792 patients
(1.9 ADRs per patient). The most frequent rSK-related
ADRs were hypotension, arrhythmias, chills, tremors,
vomiting, and nauseas (Table 2). Allergy was recorded in
47 patients, 34 of them (72%) only with skin rash. Hem-
orrhage was notified only in 43 patients. ADRs present in
less than 5 patients each, included dizziness, dyspnea,
arterial hypertension, unspecified pain, paleness, rubor,
headache, diarrhea and others.
The causality assessment showed that 1419 (94.9%) of
the total ADRs were classified as possibly associated with
the study medication. Probable and doubtful associations
were considered in 63 (4.2%) and 6 (0.4%) of suspected
reactions, respectively. Definite reactions were only con-
firmed in one patient with allergic reactions. The informa-
tion about eight adverse events was not sufficient for a
proper causality assessment.
Of the overall number of suspected ADRs, severity was
classified as mild in 564 (37.7%), moderate in 573
(38.3%), severe in 149 (10.0%), and 63 (4.2%) were very
severe. Severity was not classified in 147 (9.8%) reactions.
Considering the maximal severity to which the patient
was exposed, 53 (6.7%) subjects had at least one very
severe reaction, which was described for hypotension,
arrhythmias and hemorrhage. Of the remaining patients,
104 (13.1%) were exposed to at least one severe reaction.
Definitive discontinuation due to ADRs was observed in
54 (6.8% of those with ADRs) patients. Hypotension,
arrhythmias and vomiting were the main causes of treat-
ment withdrawal. Hypotension was also the ADR most
frequently leading to temporal SK infusion discontinua-
tion, which was required for the adequate control of
Table 1: Baseline characteristics of the patients (N = 1660)
Characteristic n (% of total)*
Gender
Male 1183 (71.3%)
Female 430 (25.9%)
Not specified 47 (2.8%)
Ethnicity
White 1116 (67.2%)
Mestizo 300 (18.1%)
Black 154 (9.3%)
Chinese 8 (0.5%)
Not specified 82 (4.9%)
Age (yr) total (183 not specified) 61.6 ± 13.0
Onset-infusion time (hours) 4.9 ± 3.7
Previous SK
< 1 year 5 (0.3%)
> 1 year 9 (0.5%)
Concomitant therapy
Aspirin 1341 (80.8%)
Beta-blockers 943 (56.8%)
Nitrosorbide 258 (15.5%)
Lidocaine 66 (3.9%)
Pentaerythritol tetranitrate 45 (2.7%)
Others 641 (38.6%)
*Continuous variables are presented as Mean ± SDBMC Clinical Pharmacology 2005, 5:5 http://www.biomedcentral.com/1472-6904/5/5
Page 4 of 7
(page number not for citation purposes)
27.7% of the patients experiencing this reaction. The
appropriate management of this event included infusion
rate reduction, infusion discontinuation, Trendelenburg's
position, volume expansion and vasopressors.
ADR occurrence was related to the time between symp-
toms onset and SK infusion, both in univariate and mul-
tivariate analyses. Patients who received SK ≤ 3 hours were
more likely to have any ADR as compared to those receiv-
ing the infusion after 3 hours (odds ratio 1.5, 95% CI: 1.2
– 1.8). Individual analysis for each suspected ADR
showed that arrhythmias were the most time-influenced,
being more frequent this event in patients who received
SK ≤ 3 h (95% CI: 1.26 – 2.18). The same was true for
hypotension (1.08 – 1.85), chills (1.11 – 2.08), and vom-
iting (1.13 – 2.18). Multivariate analyses confirmed these
associations for arrhythmias and hypotension, but for
chills and vomiting none of the models obtained were
reliable.
Out of the 1660 patients reported, 72 (4.3%) died. Death
causes are summarized in Table 3. Cardiac causes (pump
failure, arrhythmias, wall rupture), associated mainly with
the patient's clinical state, were the most frequent
(79.2%). Hemorrhagic stroke was reported as fatal in 3
cases and was the only cause of death that could be
directly explained by the use of the study medication.
Univariate analyses with baseline variables showed that
mortality was directly related to older age (p = 1.0 × 10-7)
and female gender (p = 1.7 × 10-4). Patients recorded as
dead were 10.1 (95% CI: 7.0 to 13.2) years older than sur-
vivors. None of the logistic regression models for the mul-
tivariate analysis of the effect of age and gender on
mortality was adequate, probably due to the small
number of deaths in the sample. Arrhythmias was the
only suspected ADR significantly related with death (p =
4.2 × 10-5). Mortality was 3 times more probable in
patients suffering arrhythmias than in those without this
event (odds ratio 3.1, 95% CI: 1.8 to 5.1).
Discussion
This pharmacovigilance study was performed to further
investigate the rSK safety profile in the treatment of AMI
patients in clinical practice. Although a national, sponta-
neous reporting scheme for monitoring all market drugs
exists in Cuba, rSK surveillance operated as a separate
national system. Using a different ADR report form, this
system provided specific information about a thrombo-
lytic drug that otherwise was not possible to obtain (e.g.
symptom-infusion time) and also contributed to encour-
age the number of reports. Results of this study showed a
post-marketing safety profile for rSK similar to those sug-
gested in previous clinical trials.
Spontaneous reporting is the most widely used method
for pharmacovigilance, but is associated with considera-
ble under-reporting rate [11]. In fact 29,753 rSK doses
were distributed throughout the country during the
period studied (Heber Biotech, personal communica-
tion). Apart from other minor rSK uses, this represents
approximately 5.6% of the number of doses used
throughout the country in AMI patients. This figure is sim-
ilar to those showed in other spontaneous reporting
schemes [12]. Various possible reasons for not reporting
have been identified, including uncertainty as to whether
the reaction was caused by a drug, trivial or well known
ADRs, unawareness of the need to report ADRs, not
enough time and the thought that it is too bureaucratic
[13]. All of the above mentioned factors could have influ-
enced the under-reporting observed in this study. In
accordance with other spontaneous reporting systems
[11], it was not possible to estimate ADRs incidence rates
because the numerator was affected by under-reporting
and the accurate number of subjects treated (denomina-
tor) was unknown.
Table 3: Causes of death
Cause n % of total deaths
Cardiac causes
Pump failure 32 44.4
Arrhythmias 15 20.8
Wall rupture 10 13.9
Non cardiac causes
Hemorrhagic stroke 3 4.2
Pulmonary embolism 1 1.4
Hypoxic encephalopathy 1 1.4
Sepsis 1 1.4
Unknown 91 2 . 5
Total 72 100
Table 2: Suspected adverse reactions to streptokinase
ADR n %*
Hypotension 285 36.0
Arrhythmias 281 35.5
Chills 212 26.8
Tremors 197 24.9
Vomiting 187 23.6
Nauseas 103 13.0
Allergy 47 5.9
Bleeding 43 5.4
Fever 41 5.2
Lumbar pain 10 1.3
Sweating 9 1.1
Muscular cramp 5 0.6
Others 76 9.6
* % of total patients with ADR, n = 792.BMC Clinical Pharmacology 2005, 5:5 http://www.biomedcentral.com/1472-6904/5/5
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Time between symptoms and infusion is a critical variable
for success of thrombolysis [2,3]. Since the results
obtained up to 1995 in the national extension study [8],
more experience with the procedures and organizational
measures in the heath care system could have improved
the time to thrombolysis. However, in the present study
this time did not differ significantly from the previous
period. This was probably influenced by the under-report-
ing and do not reflect what actually happened in practice.
Currently, the implementation of new organizational
actions for the nationwide extension of thrombolysis to
the pre-hospital level will surely have a greater impact on
this aspect.
Some deviations from the approved indications were
observed in routine clinical practice. Although rSK has
been approved for routine use within 12 h, 18 patients
were reported as receiving the drug after 12 h of symptoms
onset. On other hand, the proportions of patients that
received aspirin and beta blockers were smaller than pre-
viously reported in TERIMA-2 study, where a significant
benefit was demonstrated for both drugs.
The most frequent suspected ADRs associated to rSK ther-
apy were hypotension and arrhythmias. This is consistent
with the safety profile observed in previous clinical trials.
Both events can also be explained by AMI physiopathol-
ogy and sometimes by other concomitant drugs, so it was
difficult to establish a casual relationship with the study
medication and all were classified as possible. Hypoten-
sion has been described as a transient event that can be
related to SK infusion rate [14,15]. Thus, it is recom-
mended to reduce the infusion rate as its initial approach.
Arrhythmias have been considered as reperfusion signs
after thrombolytic therapy [16], but are also important
complications in the course of AMI. Despite the use of
thrombolytic therapy, in-hospital ventricular arrhythmias
have been associated with higher 30-day and 1-year mor-
tality rates [17,18]. Patients treated earlier after coronary
occlusion, when risk is greatest, are more likely to develop
ventricular fibrillation [19], which can explain why
arrhythmias were more frequent in patients who received
SK ≤ 3 h in this study.
Bleeding was notified in 43 patients, of whom only 8 were
considered as serious. Hemorrhagic stroke, which is the
most severe bleeding complication of fibrinolytic therapy,
was reported only in 3 patients (all fatal). This is consist-
ent with the low hemorrhagic stroke rate observed previ-
ously in the TERIMA-2 trial (0.3%).
Because SK is an antigenic bacterial protein, physicians
need to be aware that some patients experience allergic
reactions. Following rSK administration, a significant
increase of anti-SK antibodies binding and neutralization
titers persisting for 6 months or more have been described
[7]. Therefore, concern about SK re-administration exists
since it is possible that these antibodies cause allergic reac-
tions or neutralize a further SK dose with the consequent
ineffectiveness. Interestingly, 14 patients (5 < 1 year) with
antecedent of exposure to SK were reported in this phar-
macovigilance and none of them experienced allergic
reactions nor account for in-hospital death.
According to the definitions used in this study, at least
19.8% of patients with ADR had a serious one (sum of
severe and very severe ADRs). This relatively high propor-
tion is a tendency of spontaneous reporting schemes,
since under-reporting involves mainly the less severe and
the well known effects [11] so that severe reactions are
more likely reported. However, few patients withdrew due
to ADRs, emphasizing that prompt recognition and
appropriate symptoms handling result in adequate treat-
ment compliance. The in-hospital lethality rate was low
but under-reporting could also affect the interpretation of
this variable.
Definite reaction assessment was difficult because SK is
administered once and rechallenge information is usually
not available. Also, many of the SK associated reactions
can be explained by concurrent diseases or other drugs as
well. Ideally, both, the causality assessment and severity
analysis should have been performed by two individuals
at the investigation site, separately and then agreement
determined. This was not done for practical reasons, since
there was only one NNP member at each hospital and
thus the evaluation had to be done by this person consid-
ering the criteria from the reporting physician, with the
subsequent bias derived from application of subjective
scales.
Recombinant tissue plasminogen activator (tPA) or its
derivatives are recommended by ACC/AHA guidelines to
be used in patients who present early after onset of chest
pain or symptoms and in those with previous administra-
tion of streptokinase and at low risk of intracranial hem-
orrhage [20]. However, this product is much more
expensive than SK and not all countries can afford its gen-
eral use, especially those with a general health reimburse-
ment policy. Furthermore, a meta-analysis of large trials
comparing SK vs. tPA did not demonstrate any clear differ-
ences in net clinical outcome because the beneficial cardi-
ovascular effects of tPA is abated by an excess of
hemorrhagic stroke [21].
The favorable safety profile achieved with rSK in this and
previous studies, together with its demonstrated efficacy
and its adequate cost, justifies the extension of this treat-
ment in clinical practice as a reperfusion therapy for AMI
patients. Recent reports about deviations from quality ofBMC Clinical Pharmacology 2005, 5:5 http://www.biomedcentral.com/1472-6904/5/5
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different SK preparations [22,23], raise the importance of
a stringent regulation for this product. These reports
should be backed up by clinical data [24]. Therefore,
results from previous clinical trials and this pharmacovig-
ilance study, along with an appropriate quality control
system [25], support the recognized impact of Cuban rSK
on AMI mortality in the country.
As in other countries, ischemic heart disease is the major
cause of death in Cuba (18.8% of all deaths in 2004;
135.4 per 100000 inhabitants) [26]. The possibility to
extend thrombolytic therapy with a safe homemade prod-
uct is an example of how local biotechnology can influ-
ence on one of the main public health problems with a
favorable cost/benefit balance, not possible in a develop-
ing country with an imported drug, which would had
meant a significant economic burden for the public health
system.
Conclusion
In this study, no new signals of previously unknown
adverse events were reported, and the nature and severity
of the reported events were consistent with information
known about rSK from clinical trials. New directions
about thrombolysis are emerging in the country, includ-
ing the use of a new albumin-free formulation [27,28],
pre-hospital extension of the procedure, and new indica-
tions approval. Therefore, the continuity of this pharma-
covigilance would be of inestimable value for safety
monitoring of the product.
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